IR@PKUHSC  > 北京大学深圳医院
学科主题临床医学
A New PCR-Based Mass Spectrometry System for High-Risk HPV, Part II Clinical Trial
Du, Hui1; Yi, Ji2; Wu, Ruifang1; Belinson, Suzanne E.3; Qu, Xinfeng3; Yang, Bin4; Wang, Chun1; Yi, Xin2; Belinson, Jerome L.1,5
关键词Screening Cervical cancer Human papillomavirus HPV Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry system MALDI-TOF
刊名AMERICAN JOURNAL OF CLINICAL PATHOLOGY
2011-12-01
DOI10.1309/AJCPJDAORUY4EYR6
136期:6页:920-923
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pathology
研究领域[WOS]Pathology
关键词[WOS]CERVICAL-CANCER ; DETECT ; DNA ; PERFORMANCE ; CYTOLOGY
英文摘要

This was a population-based clinical trial of a polymerase chain reaction based multiplex high-risk human papillomavirus (HR-HPV) assay using mass spectrometry (MassARRAY [Sequenom, San Diego, CA] matrix-assisted laser desorption/ionization time-of-flight mass spectrometry system [MALDI-TOF]). Participants were 10,000 women between the ages of 25 and 59 years in Guangdong Province, China (SHENCCAST II Study). All women collected a self-sample (tested with Cervista [Hologic, Marlborough, MA] and MALDI-TOF) followed by a clinician-collected cervical sample (for cytology, Hybrid Capture 2 [HC2; Qiagen, Gaithersburg, MD], Cervista, and MALDI-TOF). Patients with any abnormal result were asked to return for colposcopy and biopsies.

This analysis included the data for 8,556 women. The sensitivity values for cervical intraepithelial neoplasia (CIN) 3 or worse for a direct cervical sample were 97.9%, 95.1%, and 94.3 for HC2, Cervista, and MALDI-TOF, respectively (P >.05). The sensitivity for CIN 3 or worse for a self-collected sample tested with MALDI-TOF was also 94.3%, which was similar to a clinician-obtained endocervical sample assayed with the 3 HR-HPV assays. MALDI-TOF combined with a self-collected sample provides a highly sensitive, high-throughput, low-cost-per-case assay for mass screening.

语种英语
WOS记录号WOS:000297274500013
资助机构Shenzhen Female Doctors&prime ; Association, Shenzhen, China ; Hologic, Marlborough, MA ; Preventive Oncology International, Cleveland Heights, OH
引用统计
被引频次:11[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66944
专题北京大学深圳医院
作者单位1.Peking Univ, Shenzhen Hosp, Shenzhen, Peoples R China
2.BGI, Shenzhen, Peoples R China
3.Prevent Oncol Int, Cleveland Hts, OH USA
4.Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA
5.Cleveland Clin, Womens Hlth Inst, Cleveland, OH 44106 USA
推荐引用方式
GB/T 7714
Du, Hui,Yi, Ji,Wu, Ruifang,et al. A New PCR-Based Mass Spectrometry System for High-Risk HPV, Part II Clinical Trial[J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY,2011,136(6):920-923.
APA Du, Hui.,Yi, Ji.,Wu, Ruifang.,Belinson, Suzanne E..,Qu, Xinfeng.,...&Belinson, Jerome L..(2011).A New PCR-Based Mass Spectrometry System for High-Risk HPV, Part II Clinical Trial.AMERICAN JOURNAL OF CLINICAL PATHOLOGY,136(6),920-923.
MLA Du, Hui,et al."A New PCR-Based Mass Spectrometry System for High-Risk HPV, Part II Clinical Trial".AMERICAN JOURNAL OF CLINICAL PATHOLOGY 136.6(2011):920-923.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Du, Hui]的文章
[Yi, Ji]的文章
[Wu, Ruifang]的文章
百度学术
百度学术中相似的文章
[Du, Hui]的文章
[Yi, Ji]的文章
[Wu, Ruifang]的文章
必应学术
必应学术中相似的文章
[Du, Hui]的文章
[Yi, Ji]的文章
[Wu, Ruifang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。